RDHL — Redhill Biopharma Income Statement
0.000.00%
Last trade - 00:00- $4.99m
- $2.09m
- $0.29m
Annual income statement for Redhill Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 85.8 | 61.8 | 0 | 0 | 0.286 |
| Cost of Revenue | |||||
| Gross Profit | 45.3 | 28.5 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 167 | 105 | 9.55 | 6.47 | 8.23 |
| Operating Profit | -81.1 | -42.8 | -9.55 | -6.47 | -7.94 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -97.7 | -71.7 | -18.5 | 0.36 | -8.08 |
| Net Income After Taxes | -97.7 | -71.7 | -18.5 | 0.36 | -8.08 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -97.7 | -71.7 | 23.9 | -8.27 | -0.429 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -97.7 | -71.7 | 23.9 | -8.27 | -0.429 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -4.77 | -2.89 | -0.007 | 0 | -0 |